Business
Moderna’s stock has surged 488% in 2020: Is it a buy for 2021?
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
All eyes were on the biotech Moderna (NASDAQ: MRNA) in 2020. It wasn’t quite a popular name in the pharmaceutical space, as it has no approved products on the market yet. But its sudden entry in the COVID-19 vaccine competition grabbed a lot of attention, and it became the second company to win approval in a race with dozens of players. No wonder its stock has surged 488% so far this year, while the S&P 500 has gained 16%.
On Dec. 11, Pfizer (NYSE: PFE) and its German biotech partner BioNTech (NASDAQ: BNTX) became the…
-
Noosa News9 hours agoTwo teenagers and two adults rushed to hospital in life-threatening conditions after shocking Lawnton house fire
-
Noosa News10 hours agoFatal traffic crash, Noosa – Sunshine Coast
-
Noosa News11 hours agoA secret scheme and plans to expel former leaders — here’s what we’ve heard from Queensland’s inquiry into the CFMEU
-
Business10 hours agoTop brokers name 3 ASX shares to buy next week 23 November 2025